Regado Biosciences says evaluating strategic alternatives

Sept 24 (Reuters) - Regado Biosciences Inc said it is evaluating a broad range of strategic alternatives, a month after the company terminated enrollment in a late-stage trial of its lead drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.